U.S. FDA Accepts for Review the Biologics License Application for Pfizer ’s Investigational Pentavalent Meningococcal Vaccine Candidate (MenABCWY) in Adolescents
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
NEW YORK--(BUSINESS WIRE) December 28, 2022 -- Pfizer Inc. (NYSE:PFE) today...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials
More News: Clinical Trials | Men | Meningitis | Meningitis Vaccine | Pfizer | Pharmaceuticals | Vaccines